摘要
目的观察过氧化物酶体增殖体激活受体γ(PPAR-γ)激活剂罗格列酮对糖基化终末产物(AGEs)诱导的大鼠肾系膜细胞纤溶酶原激活物抑制剂1(PAI-1)变化的影响。方法ELISA测定PAI-1蛋白含量,底物发色法检测纤溶酶原激活物(PA)活性,酶谱法分析基质金属蛋白酶(MMPs)活性。结果AGEs(25～200mg/L)可不同程度上调系膜细胞PAI-1表达,降低PA活性,给予罗格列酮(2.5～10mmol/L)可减轻AGEs(100mg/L)引起的PAI-1表达上调,并增加PA和MMP-2活性。结论罗格列酮减轻AGEs引起的PAI-1表达增加,提高PA和MMP-2的活性。
Objective To investigate the effect of peroxisome proliferator- activated receptor-γ （PPAR-γ） agonist rosiglitazone on advanced glycation end products （AGEs）-induced plasminogen activator inhibitor 1 （PAI-1） in rat mesangial cells. Methods PAI-1 protein content was detected by ELISA and plasminogen activator（PA） activity was analyzed by PA activity assay kit. The matrix metalloproteinase （MMPs） activities were detected by zymography. Results Rosiglitazone （2.5 - 10mmol/L） can ameliorate AGEs（100mg/L）-induced PAI-1 expression of mesangial cell and increase PA and MMP-2 activities accordingly. Conclusions Rosiglitazone can ameliorate AGEs -induced PAI-1 expression and increase PA and MMP-2 activities.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2008年第2期121-123,共3页
Chinese Journal of Diabetes
基金
吉林省科技厅资助项目(200505239)
